Literature DB >> 28484833

Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion.

Irini Chatziralli1,2, George Theodossiadis3, Panagiotis Theodossiadis3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28484833     DOI： 10.1007/s00417-017-3682-1

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  7 in total

1.  Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.

Authors:  Yuichiro Ogura; Johann Roider; Jean-François Korobelnik; Frank G Holz; Christian Simader; Ursula Schmidt-Erfurth; Robert Vitti; Alyson J Berliner; Florian Hiemeyer; Brigitte Stemper; Oliver Zeitz; Rupert Sandbrink
Journal:  Am J Ophthalmol       Date:  2014-07-25       Impact factor: 5.258

2.  Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.

Authors:  Irini Chatziralli; George Theodossiadis; Marilita M Moschos; Panagiotis Mitropoulos; Panagiotis Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-18       Impact factor: 3.117

3.  RANIBIZUMAB FOR RETINAL VEIN OCCLUSION: Predictive Factors and Long-Term Outcomes in Real-Life Data.

Authors:  Irini Chatziralli; George Theodossiadis; Alexandros Chatzirallis; Efstratios Parikakis; Panagiotis Mitropoulos; Panagiotis Theodossiadis
Journal:  Retina       Date:  2018-03       Impact factor: 4.256

4.  Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.

Authors:  Jeffrey S Heier; W Lloyd Clark; David S Boyer; David M Brown; Robert Vitti; Alyson J Berliner; Husain Kazmi; Yu Ma; Brigitte Stemper; Oliver Zeitz; Rupert Sandbrink; Julia A Haller
Journal:  Ophthalmology       Date:  2014-03-27       Impact factor: 12.079

5.  Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.

Authors:  Peter A Campochiaro; David M Brown; Carl C Awh; S Young Lee; Sarah Gray; Namrata Saroj; Wendy Yee Murahashi; Roman G Rubio
Journal:  Ophthalmology       Date:  2011-06-29       Impact factor: 12.079

6.  Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.

Authors:  John A Wells; Adam R Glassman; Allison R Ayala; Lee M Jampol; Neil M Bressler; Susan B Bressler; Alexander J Brucker; Frederick L Ferris; G Robert Hampton; Chirag Jhaveri; Michele Melia; Roy W Beck
Journal:  Ophthalmology       Date:  2016-02-27       Impact factor: 12.079

7.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245
  7 in total
  1 in total

1.  Multimodal OCT Reflectivity Analysis of the Cystoid Spaces in Cystoid Macular Edema.

Authors:  Roberta Farci; Alexandre Sellam; Florence Coscas; Gabriel J Coscas; Giacomo Diaz; Pietro Emanuele Napoli; Eric Souied; Maria Silvana Galantuomo; Maurizio Fossarello
Journal:  Biomed Res Int       Date:  2019-03-20       Impact factor: 3.411
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.